               SEQUENCE LISTING

<110> ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES
& THERAPIES A4TEC - ASSOCIAÇÃO

<120> HYDROGEL COMPOSITION FOR SOLID TUMORS  

<130> P670.4 WO

<150> PT117212 
<151> 2021-05-06

<160> 12

<170> BiSSAP 1.3.6

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> RGDS

<400> 1
Arg Gly Asp Ser 
1               

<210> 2
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> fibronectin inhibitor peptide

<400> 2
Gly Arg Gly Asp Ser Pro Lys 
1               5           

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> cyclicized RGD-containing pentapeptide

<220> 
<221> MOD_RES
<222> 5
<223> METHYLATION
      MeVal

<300> 
<301> David A Reardon, Bart Neyns, Michael Weller, Joerg Christian
      Tonn, Louis Burt Nabors & Roger Stupp
<302> Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor
      in development for glioblastoma and other malignancies
<303> Future Oncology
<304> 7
<305> 3
<306> 339-54
<307> 2011

<400> 3
Arg Gly Asp Phe Xaa 
1               5   

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> RGD-containing cyclic octapeptide

<220> 
<221> MOD_RES
<222> 5
<223> AMIDATION

<220> 
<221> NON_STD
<222> 5
<223> 1-naphthylalanine

<300> 
<301> Aaron Silva, Wenwu Xiao, Yan Wang, Wei Wang, Heng Wei Chang,
      James B. Ames, Kit S. Lam and Yonghong Zhang
<302> Structure–Activity Relationship of RGD-Containing Cyclic
      Octapeptide and αvβ3 Integrin Allows for Rapid Identification of
      a New Peptide Antagonist
<303> International Journal of Molecular Sciences
<304> 21
<305> 9
<306> 3076

<400> 4
Gly Arg Gly Asp Ala 
1               5   

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<221> MOD_RES
<222> 1
<223> Acetylation

<220> 
<223> ATN-161

<220> 
<221> MOD_RES
<222> 5
<223> AMIDATION

<300> 
<301> Fernando Doñate; Graham C. Parry; Yuval Shaked; Harvey Hensley;
      Xiaojun Guan; Ivy Beck; Ziva Tel-Tsur; Marian L. Plunkett; Mari
      Manuia; David E. Shaw; Robert S. Kerbel; Andrew P. Mazar
<302> Pharmacology of the novel antiangiogenic peptide ATN-161
      (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in
      several preclinical models of angiogenesis and tumor growth
<303> Clinical Cancer Research
<304> 14
<305> 7
<306> 2137-2144
<307> 2008

<400> 5
Pro His Ser Cys Asn 
1               5   

<210> 6
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> Vitronectin inhibitor 1

<300> 
<301> Yoonsuk Lee, Dong-Ku Kang, Soo-Ik Chang, Moon Hi Han, In-Cheol
      Kang
<302> High-throughput screening of novel peptide inhibitors of an
      integrin receptor from the hexapeptide library by using a protein
      microarray chip
<303> Journal of Biomolecular Screening
<304> 9
<305> 8
<306> 687-694
<307> 2004

<400> 6
His Gly Asp Val His Lys 
1               5       

<210> 7
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> Vitronectin inhibitor 2

<300> 
<301> Yoonsuk Lee, Dong-Ku Kang, Soo-Ik Chang, Moon Hi Han, In-Cheol
      Kang
<302> High-throughput screening of novel peptide inhibitors of an
      integrin receptor from the hexapeptide library by using a protein
      microarray chip
<303> Journal of Biomolecular Screening
<304> 9
<305> 8
<306> 687-694
<307> 2004

<400> 7
His Ser Asp Val His Lys 
1               5       

<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> Laminin inhibitor 1

<300> 
<301> K M Yamada, D W Kennedy
<302> Peptide inhibitors of fibronectin, laminin, and other adhesion
      molecules: Unique and shared features.
<303> Journal of Cellular Physiology
<304> 130
<305> 1
<306> 21-28.
<307> 1987

<400> 8
Ser Asp Gly Arg 
1               

<210> 9
<211> 12
<212> PRT
<213> Artificial Sequence


<220> 
<223> Laminin inhibitor 2

<300> 
<301> M Lourdes Ponce, Suguru Hibino, Agata M Lebioda, Mayumi
      Mochizuki, Motoyoshi Nomizu, Hynda K Kleinman
<302> Identification of a potent peptide antagonist to an active
      laminin-1 sequence that blocks angiogenesis and tumor growth
<303> Cancer Research
<304> 63
<305> 16
<306> 5060-5064
<307> 2003

<400> 9
Asp Phe Lys Leu Phe Ala Val Tyr Ile Lys Tyr Arg 
1               5                   10          

<210> 10
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> Tenascin C inhibitor 1

<300> 
<301> Mee Young Kim, Ok Ran Kim, Yong Seok Choi, Heuiran Lee, Keerang
      Park, Choon-Taek Lee, Keon Wook Kang, Sunjoo Jeong
<302> Selection and characterization of tenascin C targeting peptide
<303> Molecules and Cells
<304> 33
<305> 1
<306> 71-77

<400> 10
Phe His Lys His Lys Ser Pro Ala Leu Ser Pro Val Gly Gly Gly 
1               5                   10                  15  

<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> Tenascin C inhibitor 2

<300> 
<301> Prakash Lingasamy, Allan Tobi, Kaarel Kurm, Sergei Kopanchuk,
      Aleksander Sudakov, Markko Salumäe, Tõnu Rätsep, Toomas Asser,
      Rolf Bjerkvig & Tambet Teesalu
<302> Tumor-penetrating peptide for systemic targeting of Tenascin-C
<303> Scientific Reports
<304> 10
<305> 1
<306> 5809
<307> 2020

<400> 11
Ala Gly Arg Gly Arg Leu Val Arg 
1               5               

<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Collagen (and laminin) inhibitor (cyclic peptide)

<300> 
<301> J Ivaska, J Käpylä, O Pentikäinen, A M Hoffrén, J Hermonen, P
      Huttunen, M S Johnson, J Heino
<302> Peptide Inhibiting the Collagen Binding Function of Integrin
      alpha2I Domain
<303> Journal of Biological Chemistry
<304> 274
<305> 6
<306> 3513-3521
<307> 199

<400> 12
Cys Thr Arg Lys Lys His Asp Asn Ala Gln Cys 
1               5                   10      

